The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing

Recruiting now

Conditions studied: Patients Undergoing Routine Health Care, Heart Diseases, Inflammatory Bowel Diseases, Autoimmune Disease, Inflammatory Disease, Blood Coagulation Disorders, Hepatitis C, Non-Metastatic Neoplasm

In brief

The purpose of this study is to collect DNA samples from patients undergoing routine care at the University of Chicago. These samples will be tested for differences in genes that may suggest greater risk of side effects or chance of increased benefit from certain medications. The results will be made available to the patient's treating physician and the researchers will track whether or not this information is used in routine health care.

Key facts

Study ID

NCT01280825

Run by

University of Chicago

People needed

1200

Starts

2011-01-14

Expected to finish

2027-12-14

Last updated by the study team

2026-03-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Receiving ongoing, out-patient care at the University of Chicago Medical Center under the routine care of a physician participating in this trial
• Life expectancy of at least 3 years
• Must be 18 years or older
• Must be taking at least 1 (but not more than 6) prescription medications at the time of enrollment OR be 65 years or older OR be reasonably expected to require the use of a prescription medication within the next 5 years
• Patients with certain diseases, or likely to receive or be receiving certain drugs, will be targeted particularly for enrollment in order to enrich the study for patients likely to have pharmacogenetically relevant interactions, including, but not limited to:
• Patients requiring specialized cardiology care
• Patients with inflammatory bowel diseases
• Patients with systemic autoimmune or inflammatory diseases
• Patients requiring long-term oral anticoagulation
• Patients with hepatitis C
• Patients with non-metastatic cancer

You may not qualify if…

• Patients with acute or chronic disease which could be reasonably expected to result in the patient's death within the next 3 years.
• Patients who have undergone, or are being actively considered for, liver or kidney transplantation.
• Inability to understand and give informed consent to participate.

Where it is running

• University of Chicago Medical Center — Chicago, Illinois, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.